Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy

J Am Coll Cardiol. 2005 Sep 20;46(6):1036-42. doi: 10.1016/j.jacc.2005.05.067.

Abstract

Objectives: This study aimed to evaluate the role of gene expression for predicting myocardial recovery in recent-onset cardiomyopathy.

Background: Apoptosis may limit ventricular recovery. We examined the myocardial expression of Fas, Fas ligand (FasL), tumor necrosis factor (TNF)-alpha, and TNF receptor 1 (TNFR1), and myocardial recovery in patients from the multicenter Intervention in Myocarditis and Acute Cardiomyopathy (IMAC) study.

Methods: Endomyocardial biopsy samples were obtained in 20 patients with recent-onset (<6 months) idiopathic dilated cardiomyopathy (left ventricular ejection fraction [LVEF] < or =0.40). The LVEF was assessed at baseline and at 6 and 12 months by nuclear scans. Myocardial expression was assessed by ribonuclease (RNase) protection, normalized to a constitutively active gene (glyceraldehydes 3-phosphate dehydrogenase [GAPDH]) and reported as percent GAPDH expression. The change in LVEF at 6 and 12 months was compared by tertiles of expression.

Results: For all patients (14 men, 6 women; age 46.5 +/- 10.7 years), the mean LVEF was 0.28 +/- 0.05 at baseline and 0.40 +/- 0.14 at six months. Patients in the highest tertile of Fas expression had minimal improvement at six months (DeltaEF = 0.03 +/- 0.05) when compared with the intermediate (DeltaEF = 0.10 +/- 0.13) and lowest tertiles (DeltaEF = 0.21 +/- 0.11, change in LVEF by tertile, p = 0.006). A similar relationship was seen with TNFR1 expression (highest tertile, DeltaEF = 0.06 +/- 0.07; lowest tertile, DeltaEF = 0.21 +/- 0.11, p = 0.02). In contrast with Fas and TNFR1, expression of TNF-alpha and FasL did not predict recovery of LV function.

Conclusions: In cardiomyopathy of recent onset, increased expression of Fas and TNFR1 was associated with minimal recovery of LV function. Apoptosis limits myocardial recovery, and represents a potential target for therapeutic intervention.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Cardiomyopathies / drug therapy
  • Cardiomyopathies / metabolism*
  • Cardiomyopathies / physiopathology*
  • Fas Ligand Protein
  • Female
  • Humans
  • Male
  • Membrane Glycoproteins / biosynthesis*
  • Middle Aged
  • Receptors, Tumor Necrosis Factor, Type I / biosynthesis*
  • Recovery of Function
  • Time Factors
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Tumor Necrosis Factors / biosynthesis*
  • Ventricular Function, Left*
  • fas Receptor / biosynthesis*

Substances

  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins
  • Receptors, Tumor Necrosis Factor, Type I
  • Tumor Necrosis Factor-alpha
  • Tumor Necrosis Factors
  • fas Receptor